Kim Kwang Min, Kim Ho-Cheol, Jeon Kyung-Nyeo, Kim Hoon-Gu, Kang Jung Hun, Hahm Jong Ryeal, Lee Gyeong-Won
Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju 660-702, Korea.
Yonsei Med J. 2008 Feb 29;49(1):155-8. doi: 10.3349/ymj.2008.49.1.155.
A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH. Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Bronchoscopy guided transbronchial lung biopsy revealed interstitial thickening and type II pneumocyte activation, compatible with interstitial pneumonitis. After treatment with prednisolone a complete resolution of the dyspnea was observed. The patient was well on routine follow-up at the outpatient clinic, with no progression of lymphoma or interstitial pneumonitis.
一名69岁男性于2004年2月被诊断为IV期结外边缘区B细胞淋巴瘤，累及纵隔淋巴结、肺实质和骨髓，乳酸脱氢酶水平较高。在接受第5疗程利妥昔单抗-环磷酰胺、长春新碱、多柔比星、泼尼松（Rituximab-CHOP）化疗后出现气短。支气管镜引导下经支气管肺活检显示间质增厚和II型肺泡上皮细胞活化，符合间质性肺炎表现。使用泼尼松治疗后，呼吸困难完全缓解。患者在门诊进行常规随访时情况良好，淋巴瘤或间质性肺炎均无进展。
